{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stem+Cell+Transplantation+%28SCT%29&page=4",
    "query": {
      "intervention": "Stem Cell Transplantation (SCT)",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 164,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stem+Cell+Transplantation+%28SCT%29&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stem+Cell+Transplantation+%28SCT%29&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T11:59:12.127Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00025662",
      "title": "Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft vs Host Disease",
        "Myelodysplastic Syndromes",
        "Leukemia",
        "Leukemia, Myeloid",
        "Leukemia, Myelomonocytic, Chronic",
        "Leukemia, Lymphocytic",
        "Lymphoma",
        "Lymphoma, Mantle-cell",
        "Lymphoma, Non-Hodgkin",
        "Hodgkin Disease"
      ],
      "interventions": [
        {
          "name": "RFT5-SMPT-dgA",
          "type": "DRUG"
        },
        {
          "name": "Isolex system",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 23,
      "start_date": "2001-05",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2016-10-28",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025662"
    },
    {
      "nct_id": "NCT01744223",
      "title": "Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "BPX-501 dose 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        },
        {
          "name": "BPX-501 dose 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BPX-501 dose 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BPX-501 dose 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SCT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Bellicum Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-03",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2022-07-12",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 8,
      "location_summary": "Atlanta, Georgia • Buffalo, New York • New York, New York + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01744223"
    },
    {
      "nct_id": "NCT00632827",
      "title": "Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Navelbine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride Liposome Injection",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte-colony stimulating factor (G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Denileukin diftitox",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 21,
      "start_date": "2008-07-01",
      "completion_date": "2016-06-23",
      "has_results": true,
      "last_update_posted_date": "2020-04-27",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00632827"
    },
    {
      "nct_id": "NCT02485535",
      "title": "Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2015-09-04",
      "completion_date": "2020-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02485535"
    },
    {
      "nct_id": "NCT01643668",
      "title": "Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Stem Cell Infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2012-07",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2017-07-13",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01643668"
    },
    {
      "nct_id": "NCT05183490",
      "title": "R-MVST Cells for Treatment of Viral Infections",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epstein-Barr Virus Infections",
        "Cytomegalovirus Infections",
        "Adenovirus",
        "BK Virus Infection"
      ],
      "interventions": [
        {
          "name": "Rapidly generated virus specific T (R-MVST) cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2022-05-03",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05183490"
    },
    {
      "nct_id": "NCT07356245",
      "title": "Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T-cell Lymphoma",
        "Graft Versus Host Disease",
        "Lymphoma, T-Cell",
        "Peripheral T Cell Lymphoma",
        "T-cell Prolymphocytic Leukemia",
        "Cutaneous T Cell Lymphoma",
        "Adult T-cell Leukemia/Lymphoma",
        "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Positron emission tomography-computed tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Jonathan Brammer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2026-02-12",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07356245"
    },
    {
      "nct_id": "NCT00579917",
      "title": "Behavioral Intervention For BMT/SCT Survivors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hodgkin's Disease",
        "Leukemia",
        "Multiple Myeloma",
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy: Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care: Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2005-01",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2009-01-07",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00579917"
    },
    {
      "nct_id": "NCT00004143",
      "title": "Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Anemia",
        "Severe Aplastic Anemia",
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
        "Pure Red Cell Aplasia"
      ],
      "interventions": [
        {
          "name": "Campath, Chemo and/or TBI Allo SCT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Rizzieri, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "1999-09",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2014-12-05",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Durham, North Carolina",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004143"
    },
    {
      "nct_id": "NCT00857389",
      "title": "Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stem Cell Transplantation",
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Thymoglobulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "G-CSF (Filgrastim)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2009-03-02",
      "completion_date": "2019-03-09",
      "has_results": true,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-10-04T11:59:12.127Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00857389"
    }
  ]
}